Taipei; 28, December 2015: Braincure Biotech (ISIN:TW0001327872) has recently appointed Mr. Lee Yung Lung as the Chief Operating Officer (COO) of the company.
Mr. Lung, age 53, has served as Executive Vice President, Global Neurology and Head of International. In his new role, Mr. Lung will oversee all commercial operations as well as the company’s business development function.
“In view of the continued expansion of our commercial businesses, and the advances of our extensive pipeline, it is important to further integrate Braincure Biotech’s commercial units,” SuhonHorng, president and CEO of Braincure Biotech stated. “Bringing together these businesses to enhance our commercial and new product opportunities on a global basis is a logical step in the continued implementation of our growth strategy — and Lee Yung Lung is the ideal person to fill this new organizational role. Over the last few years, Lee Yung has led the great success and growth of our business. I am confident that we will continue meeting and exceeding our goals under his strong and capable leadership.”
Since assuming responsibilities for Braincure Biotech’s International business, the company’s sales outside the have grown consistently. A stated strategic goal of Braincure Biotech is to continue the geographic diversification of the company’s revenue base, with more than 50 percent of revenue coming from our International business.
Lee Yung Lung joined Braincure Biotech since its inception from Top Pharmaceutical Companywhere he worked for eight years, serving as Senior Vice President, Head of Global Strategic Marketing.
About Braincure Biotech:
Braincure-Biotech.com is a state-of-the-art technology research company that uses discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically similar disorders. Braincure Biotech’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. The goal of the firm is to discover and develop novel, disease modifying therapies for dementia and mechanistically similar disorders. The highly professional and acclaimed team of scientists maintains an innovative and motivating environment in which every employee has the possibility to contribute to our joint success and to grow individually.
For Media Contact:
Address: Taipei Far Eastern Plaza
No. 207, Section 2
Dun Hua South Road,
Taipei 106, Taiwan
Email: [email protected]